Use of CAR-T cells for the treatment of relapsed and refractory multiple myeloma: a systematic review
A systematic review of published articles based on randomized clinical trials was conducted to ascertain the efficacy or perspective of using CAR-T cell therapy for refractory multiple myeloma. The PubMed database was searched with the combination of terms "multiple myeloma", "refractory multiple myeloma", "CAR T-cell", and the PRISMA criteria were followed. Of the 78 articles found, only 5 were selected. The studies used different treatment protocols and four different types of CAR-T cells. All studies obtained interesting results in terms of increased progression-free survival and negative minimal residual disease responses. Some authors detected an expansion of CAR-T cells and noted dose-dependent relationship between treatment effectiveness and serum BCMA levels. Although the results were promising, a small number of patients still relapsed a few months after CAR-T cell infusion. Therefore, this new line of therapy should be further investigated, as it significantly increases progression-free survival and improves quality of life..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Brazilian Journal of Oncology - 20(2024) |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Satchie Sakamoto [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
B-cell maturation antigen |
|---|
| doi: |
10.5935/2526-8732.20240443 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ09612752X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ09612752X | ||
| 003 | DE-627 | ||
| 005 | 20240413142530.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240413s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.5935/2526-8732.20240443 |2 doi | |
| 035 | |a (DE-627)DOAJ09612752X | ||
| 035 | |a (DE-599)DOAJ4b5701291b8b4e68b17bcf5b75431390 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RC254-282 | |
| 100 | 0 | |a Satchie Sakamoto |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Use of CAR-T cells for the treatment of relapsed and refractory multiple myeloma: a systematic review |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a A systematic review of published articles based on randomized clinical trials was conducted to ascertain the efficacy or perspective of using CAR-T cell therapy for refractory multiple myeloma. The PubMed database was searched with the combination of terms "multiple myeloma", "refractory multiple myeloma", "CAR T-cell", and the PRISMA criteria were followed. Of the 78 articles found, only 5 were selected. The studies used different treatment protocols and four different types of CAR-T cells. All studies obtained interesting results in terms of increased progression-free survival and negative minimal residual disease responses. Some authors detected an expansion of CAR-T cells and noted dose-dependent relationship between treatment effectiveness and serum BCMA levels. Although the results were promising, a small number of patients still relapsed a few months after CAR-T cell infusion. Therefore, this new line of therapy should be further investigated, as it significantly increases progression-free survival and improves quality of life. | ||
| 650 | 4 | |a multiple myeloma | |
| 650 | 4 | |a immunotherapy, adoptive | |
| 650 | 4 | |a b-cell maturation antigen | |
| 650 | 4 | |a recurrence | |
| 653 | 0 | |a Neoplasms. Tumors. Oncology. Including cancer and carcinogens | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 700 | 0 | |a Vanessa Sgnaolin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Brazilian Journal of Oncology |d Sociedade Brasileira de Oncologia Clínica, Sociedade Brasileira de Cirurgia Clínica and Sociedade Brasileira de Radioterapia, 2022 |g 20(2024) |w (DE-627)DOAJ000148679 |x 25268732 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2024 |
| 856 | 4 | 0 | |u https://doi.org/10.5935/2526-8732.20240443 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/4b5701291b8b4e68b17bcf5b75431390 |z kostenfrei |
| 856 | 4 | 0 | |u https://www.brazilianjournalofoncology.com.br/details/272/en-US/uso-de-celulas-car-t-no-tratamento-de-mieloma-multiplo-recidivado-e-refratario--uma-revisao-sistematica |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2526-8732 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2024 | ||